Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C53H88N4O51S8 |
| Molecular Weight | 1853.782 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 28 / 28 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CS[C@@H](CCCCC(=O)NCCCCCC(=O)N[C@H]3[C@@H](O[C@@]4([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]5([H])[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]6([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]7([H])[C@@H](COS(O)(=O)=O)O[C@H](OC)[C@H](OS(O)(=O)=O)[C@H]7OS(O)(=O)=O)O[C@H]6C(O)=O)[C@H](OS(O)(=O)=O)[C@H]5OS(O)(=O)=O)O[C@@H]4C(O)=O)O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@@H]3OC)[C@@]1([H])NC(=O)N2
InChI
InChIKey=MUQWDYYIYNYBQD-OFHININYSA-N
InChI=1S/C53H88N4O51S8/c1-86-30-22(17-93-110(65,66)67)96-48(29(33(30)87-2)56-27(59)15-9-8-12-16-54-26(58)14-11-10-13-25-28-21(20-109-25)55-53(64)57-28)101-36-34(88-3)42(90-5)50(103-40(36)46(60)61)100-32-24(19-95-112(71,72)73)98-52(45(108-116(83,84)85)39(32)106-114(77,78)79)102-37-35(89-4)43(91-6)51(104-41(37)47(62)63)99-31-23(18-94-111(68,69)70)97-49(92-7)44(107-115(80,81)82)38(31)105-113(74,75)76/h21-25,28-45,48-52H,8-20H2,1-7H3,(H,54,58)(H,56,59)(H,60,61)(H,62,63)(H2,55,57,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)(H,77,78,79)(H,80,81,82)(H,83,84,85)/t21-,22+,23+,24+,25-,28-,29+,30+,31+,32+,33+,34-,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,48+,49-,50+,51+,52+/m0/s1
| Molecular Formula | C53H88N4O51S8 |
| Molecular Weight | 1853.782 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 28 / 28 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Idrabiotaparinux, a biotinylated idraparinux, was developed by Sanofi as a long-acting inhibitor of factor Xa. Idrabiotaparinux participated in clinical trials phase III to prevent stroke and systemic thromboembolic events in patients with atrial fibrillation. The study was prematurely terminated, because of unknown reason. In addition, the drug was involved in phase II for patients with pulmonary embolism. Sanofi has discontinued development of idrabiotaparinux.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of idraparinux and idrabiotaparinux for anticoagulant therapy. | 2009 Nov |
|
| Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. | 2011 Jan |
|
| Idrabiotaparinux treatment for venous thromboembolism. | 2012 Jan 14 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:09:33 GMT 2023
by
admin
on
Sat Dec 16 10:09:33 GMT 2023
|
| Record UNII |
H44R6RJT3S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000175130
Created by
admin on Sat Dec 16 10:09:33 GMT 2023 , Edited by admin on Sat Dec 16 10:09:33 GMT 2023
|
PRIMARY | |||
|
774531-07-6
Created by
admin on Sat Dec 16 10:09:33 GMT 2023 , Edited by admin on Sat Dec 16 10:09:33 GMT 2023
|
PRIMARY | |||
|
H44R6RJT3S
Created by
admin on Sat Dec 16 10:09:33 GMT 2023 , Edited by admin on Sat Dec 16 10:09:33 GMT 2023
|
PRIMARY | |||
|
16202213
Created by
admin on Sat Dec 16 10:09:33 GMT 2023 , Edited by admin on Sat Dec 16 10:09:33 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
CAN NEUTRALIZE IDRABIOTAPARINUX
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
